FDA Brief

Warning letters Drugs

FDA warning letter to

East Fork Cultivars

High riskIssued Dec 22, 2023Posted Dec 26, 2023Office of Unapproved Drugs and Labeling Compliance

East Fork Cultivars sold CBD products as unapproved drugs with COVID-19 and disease-treatment claims, FDA says.

What happened

FDA reviewed East Fork Cultivars' websites and social media in September 2023, not an inspection. FDA found claims that CBD products, including Rescue Rub CBD, CBD Oil, and Peak CBD Solution tinctures, could inhibit SARS-CoV-2, treat COVID-19, and had therapeutic effects for pain, inflammation, breast cancer, and epilepsy. FDA determined the products were unapproved new drugs and misbranded because their labeling lacked adequate directions for use.

What FDA found

  1. The CBD products are unapproved new drugs because FDA has not approved applications for them and they are not generally recognized as safe and effective for the claimed uses.

    sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)
  2. The products are misbranded because their labeling does not include adequate directions for use by a layperson.

    section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1); 21 CFR 201.5
  3. Website and social media claims made the CBD products intended as drugs, including claims that CBD can inhibit SARS-CoV-2 infection or treat COVID-19.

    section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  4. The company promoted CBD for pain, inflammation, breast cancer, and epilepsy, supporting drug intended use.

    section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)

What FDA wants

FDA tells the company to notify it in writing within fifteen working days of the specific steps taken to correct the violations, explain how recurrence will be prevented, and include related documentation. If corrective action cannot be completed in that time, the company must state the reason and when it will finish.

Who should pay attention

  • other CBD and hemp product marketers
  • retailers and online sellers of CBD products
  • regulatory teams reviewing website and social media claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk